FDA Approves edaravone (Radicava™) to Treat ALS...
June 1, 2017 - Featured , In the News / Politics By: Thanesha Graham, PharmD Candidate c/o 2019 – Amyotrophic lateral sclerosis (ALS) is commonly referred to as Lou Gehrig’s disease. Gehrig was an American first baseman who played 17 seasons in Major League Baseball for the New York Yankees and passed away from ALS at the age of 37. According to the Centers for Disease… |
|
Ketogenic Diets for Diabetes Mellitus and Obesity...
June 1, 2017 - Clinical , Featured By: Anna Chen, PharmD Candidate c/o 2020 – Every day the public faces an onslaught of a new fad diet that promises to prevent boredom and the feelings of restriction that regular diets are famous for. One example is the banana diet that promises to keep one satiated with the high volume and fiber content… |
|
Pharmacy Lobby Day 2017, A Student’s Perspective...
June 1, 2017 - Featured , Professional Advice / Opinions By: Zachary Reale, PharmD Candidate c/o 2018 – Every April, pharmacists and pharmacy students from all across New York State gather in Albany for Pharmacy Lobby Day. The event, organized by the Pharmacists Society of the State of New York (PSSNY), is held in collaboration with many other New York State pharmacy associations including the… |
|
Pharmacy Pearls: Current Treatment for Hepatitis C...
June 1, 2017 - Clinical , Featured By: Vicky Liu, PharmD Candidate c/o 2018 – Hepatitis is an inflammation of the liver commonly caused by viruses which can lead to self-limitation, fibrosis, cirrhosis, or liver cancer. Viral hepatitis is categorized into five types: A, B, C, D, and E. Of the five types, A, B, and C are the most prevalent in… |
|
The Prior Authorization Process and its Effect on Patie...
June 1, 2017 - Featured , In the News / Politics By: Zachary Reale, PharmD Candidate c/o 2018 – Today there are over fifty oral anticancer agents on the market and the Food and Drug Administration (FDA) have approved much of these agents within the last ten years. The number of oral anticancer agents will likely continue to grow in the near future, as more than… |
|
Valbenazine (Ingrezza®): The First FDA Approved Drug f...
June 1, 2017 - Featured , In the News / Politics By: Yan Yi Chan, PharmD Candidate c/o 2018 – Tardive dyskinesia is a movement disorder characterized by involuntary and repetitive movements of the tongue, jaw, lips, face, trunk, upper and lower extremities, and respiratory system.1 This is usually associated with the use of dopamine receptor blockers such as antipsychotic medications in treating psychiatric disorders and… |